CMED CanniMed Therapeutics Inc

CanniMed Therapeutics Inc. Announces 2017 Second Quarter Results Release Date

CanniMed Therapeutics Inc. (TSX:CMED) (“CanniMed” or the “Company”) announces that it plans to release its financial results for the three and six months ended April 30, 2017 before markets open on Monday, June 12, 2017.

About CanniMed Therapeutics Inc.

CanniMed is a Canadian-based, international plant biopharmaceutical company and a leader in the Canadian medical cannabis industry, with 15 years of pharmaceutical cannabis cultivation experience, state-of-the-art, GMP-compliant production process and world class research and development platforms with a wide range of pharmaceutical-grade cannabis products. In addition, the Company has an active plant biotechnology research and product development program focused on the production of plant-based materials for pharmaceutical, agricultural and environmental applications.

The Company, through its subsidiaries, was the first producer to be licensed under the Marihuana for Medical Purposes Regulations, the predecessor to the current Access to Cannabis for Medical Purposes Regulations. It was the sole supplier to Health Canada under the former medical marijuana system for 13 years, and has been producing safe and consistent medical marijuana for thousands of Canadian patients, with no incident of product diversion or recalls.

For more information, please visit our websites: www.cannimed.ca (patients) and www.cannimedtherapeutics.com (investors).

Notice Regarding Forward Looking Statements

This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements”. Forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved.

Forward-looking statements are based on assumptions and involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of CanniMed Therapeutics Inc. to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including the risks described in CanniMed Therapeutics Inc.’s documents filed with applicable Canadian securities regulatory authorities which may be viewed at sedar.com. The forward-looking statements included in this news release are made as of the date of this news release. CanniMed Therapeutics Inc. does not undertake to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise, unless required by applicable securities legislation.

EN
05/06/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CanniMed Therapeutics Inc

 PRESS RELEASE

CanniMed Therapeutics Inc. Announces First Quarter Results

SASKATOON, Saskatchewan--(BUSINESS WIRE)-- CanniMed Therapeutics Inc. (TSX:CMED) (“CanniMed” or the “Company”) today released its unaudited financial results of operations for the three months ended January 31, 2018. The information in this news release should be read in conjunction with the Company’s condensed consolidated interim financial statements and notes thereto (unaudited) for the three months ended January 31, 2018 and the Company’s audited consolidated financial statements and notes thereto for the year ended October 31, 20...

 PRESS RELEASE

CanniMed Therapeutics Inc. Announces Quarterly Results Release Date

SASKATOON, Saskatchewan--(BUSINESS WIRE)-- CanniMed Therapeutics Inc. (TSX:CMED) (“CanniMed” or the “Company”) announces that it plans to release its financial results for the three months ended January 31, 2018 before markets open on Monday, March 19, 2018. About CanniMed Therapeutics Inc. CanniMed is a Canadian-based, international plant biopharmaceutical company and a leader in the Canadian medical cannabis industry, with 17 years of pharmaceutical cannabis cultivation experience, state-of-the-art, GMP-comp...

 PRESS RELEASE

Changes to CanniMed Therapeutics Board Following Share Take-Up by Auro...

EDMONTON, Alberta & SASKATOON, Saskatchewan--(BUSINESS WIRE)-- Aurora Cannabis Inc. (“Aurora”) (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) and CanniMed Therapeutics Inc. (“CanniMed”) (TSX: CMED) announced today that following the successful take up and payment of approximately 86.8% of the issued and outstanding of CanniMed Shares, three Aurora Cannabis appointees will join the CanniMed Board of Directors, effective immediately. The CanniMed Board of Directors will now be comprised of: Mr. John Knowles (L...

 PRESS RELEASE

Aurora Cannabis Announces Success in Bid for CanniMed Therapeutics Thr...

SASKATOON, Saskatchewan--(BUSINESS WIRE)-- CanniMed Therapeutics Inc. (“CanniMed”) (TSX: CMED) is advised that Aurora Cannabis Inc. (“Aurora”) has been successful in its offer (the “Offer”) for all issued and outstanding common shares of the Company. The information set out in this press release is based on information provided by Aurora. The number of CanniMed common shares (the “CanniMed Shares”) tendered as at the close of business on March 8, 2018 totals 17,847,341, representing approximately 70.66% of the total outstandi...

 PRESS RELEASE

Aurora Cannabis Announces Receipt of Final Regulatory Approval for Can...

SASKATOON, Saskatchewan--(BUSINESS WIRE)-- CanniMed Therapeutics Inc. (“CanniMed”) (TSX: CMED) today announced that Aurora Cannabis Inc. (“Aurora”) announced that it has received a No Action Letter from the Competition Bureau (Canada) regarding Aurora’s offer (the "Offer") to purchase all of the issued and outstanding common shares ("CanniMed Shares") of CanniMed that Aurora does not already own. This approval by the Competition Bureau (Canada) represents the final regulatory approval required before Aurora can begin its take-up of Ca...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch